Cargando…
Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis
BACKGROUND: Amyloid-related imaging abnormalities due to haemosiderin deposition (ARIA-H) occur in patients with mild to moderate dementia due to Alzheimer's disease (AD) and have been reported with increased incidence in clinical trials of amyloid-lowering therapies under development for AD. O...
Autores principales: | Arrighi, H Michael, Barakos, Jerome, Barkhof, Frederik, Tampieri, Donatella, Jack, Clifford, Melançon, Denis, Morris, Kristen, Ketter, Nzeera, Liu, Enchi, Brashear, H Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717448/ https://www.ncbi.nlm.nih.gov/pubmed/25669746 http://dx.doi.org/10.1136/jnnp-2014-309493 |
Ejemplares similares
-
Comparing ARIA‐E severity scales and effects of treatment management thresholds
por: Klein, Gregory, et al.
Publicado: (2022) -
Bapineuzumab Alters Aβ Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy
por: Roher, Alex E., et al.
Publicado: (2013) -
Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials
por: Xu, Steven X., et al.
Publicado: (2015) -
Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation
por: Miles, Luke A., et al.
Publicado: (2013) -
Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies
por: Ivanoiu, Adrian, et al.
Publicado: (2016)